These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36248788)

  • 61. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Cui W; Luo Q; Sun SL; Xu JL; Gu H
    Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
    N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
    White MN; Piper-Vallillo AJ; Gardner RM; Cunanan K; Neal JW; Das M; Padda SK; Ramchandran K; Chen TT; Sequist LV; Piotrowska Z; Wakelee HA
    Clin Lung Cancer; 2022 May; 23(3):e210-e221. PubMed ID: 34887193
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
    Ibusuki R; Yoneshima Y; Hashisako M; Matsuo N; Harada T; Tsuchiya-Kawano Y; Kishimoto J; Ota K; Shiraishi Y; Iwama E; Tanaka K; Oda Y; Okamoto I
    Transl Lung Cancer Res; 2022 Nov; 11(11):2208-2215. PubMed ID: 36519019
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
    Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
    Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.
    Gao RL; Song J; Sun L; Wu ZX; Yi XF; Zhang SL; Huang LT; Ma JT; Han CB
    Front Pharmacol; 2022; 13():920165. PubMed ID: 36034821
    [No Abstract]   [Full Text] [Related]  

  • 69. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
    Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G
    Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study.
    Chen M; Wang Z; Liu Z; Deng T; Wang X; Chang Z; Zhang Q; Yang W; Liu N; Ji Z; Zhang X; Wang X; Peng Z; Li Y; Cao Y; Jin X; Lu H; Qu H; Tang Y; Xu C; Fang W; Zhang H; Yan D; Wang L; Li J; Zhang J; Wang Q; Xue L; Yin F; Han G; Cheng Z; Liu Q; Jin Y; Zhang Y; Li L; Cao B; Yao Y; Chen Z; Zou J; Ying J; Wei Q; Tian T; Zhao W; Li L; Zhang T; Song F; Ba YE; Li N; Gao H; Ji Y; Bao L; Zhao X; Cai J; Yuan Z; Shen L; Li J
    JCO Precis Oncol; 2023 Mar; 7():e2200463. PubMed ID: 36996375
    [TBL] [Abstract][Full Text] [Related]  

  • 71. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.
    Zhai J; Lu J; Zhang Z; Wang Y; Li X; Zhang S; Mu S; Zhi X; Ge X; Lu D; Hu Y; Wang J
    Cancer Med; 2022 May; 11(10):2043-2055. PubMed ID: 35315579
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PD-1/PD-L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta-analysis focus on PD-L1 expression level.
    Jin Z; Wang J; Sun J; Zhu C; Zhang J; Zhang B
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1794. PubMed ID: 37199321
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma.
    Huang JX; Liu B; Li Y; Li X; Ding LJ; Wang NY
    Front Oncol; 2023; 13():1204486. PubMed ID: 37664019
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer.
    Guo L; Liang J; Dai W; Li J; Si Y; Ren W; Lu Y; Chen D
    Cancer Control; 2022; 29():10732748221107590. PubMed ID: 35673884
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
    Wu Q; Wang W; Zhou P; Fu Y; Zhang Y; Shao YW; Jiang L
    Pathol Res Pract; 2020 Aug; 216(8):153043. PubMed ID: 32703503
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases.
    Qin Y; Gao G; Xie X; Zhu Z; Guan W; Lin X; Xie Z; Ming O; Chen R; Zhong N; Li S; Zhou C
    Clin Lung Cancer; 2019 May; 20(3):e329-e337. PubMed ID: 30683631
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
    Zhang F; Huang D; Zhao L; Li T; Zhang S; Zhang G; Yuan F; Zhang J; Zhang Y; Zhao Z; Cui L; Zhao J; Wang G; Cai S; Bai Y; Wang J; Hu Y
    Ther Adv Med Oncol; 2020; 12():1758835920936882. PubMed ID: 32670420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.